Lucid Diagnostics Inc.
LUCDHealthcareNASDAQMedical Devices · Last scanned Jul 22, 2026
Scan Results
Daily timeframePart of the healthcare sector, Lucid Diagnostics Inc. (LUCD) is listed under Medical Devices. The company carries a $184.4M market cap, placing it firmly in the micro-cap category. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
Market Cap
$184.4M
Beta
1.07
P/E (TTM)
—
P/E (Fwd)
-5.69
EPS (TTM)
$-0.34
EPS (Fwd)
$-0.17
ROE
—
ROA
-92.1%
Cash
$29.4M
Total Debt
$26.8M
Free CF
-$25.5M
52W Change
-13.7%
Annual Financials
Cash vs Debt
Where LUCD stands vs its 150-day and 200-day moving averages
As of the July 13, 2026 close, LUCD finished 13.79% below its 150-day moving average ($1.16) and 13.04% below its 200-day moving average ($1.15). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LUCD overbought or oversold?
At the July 13, 2026 close, LUCD's RSI(14) was 39.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Lucid Diagnostics Inc. holds $29.4M in cash against $26.8M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$25.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $500K (2021) to $4.7M (2025), reflecting a 841% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Lucid Diagnostics Inc.'s trajectory.